Globus Medical (GMED) Falls as Recent Analyst Caution Appears to Weigh on Shares

Globus Medical (GMED) is down 4.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a more cautious analyst tone that surfaced in early July, including a downgrade to hold and a separate price-target cut tied to growth concerns. There does not appear to be a fresh company press release or major new operating update today, so the decline may reflect investors reacting to softer sentiment after a strong run earlier this year.

Details:

Globus Medical’s investor relations page shows its latest press release was the first-quarter 2026 results in May, suggesting there was no obvious new company announcement behind today’s move.

In that first-quarter update, the company posted worldwide net sales of $759.9 million, up 27.0%, and lifted its 2026 non-GAAP earnings outlook while reaffirming full-year revenue guidance.

Recent sell-side commentary turned more cautious in July, with one research firm lowering its rating to hold and another trimming its price target while pointing to growth concerns.

A June SEC filing also showed shareholders approved an increase in shares available under the company’s equity incentive plan, a governance item that was disclosed earlier but may remain part of the background discussion around the stock.

Sources:

Globus Medical Investor Relations, SEC, Investing.com, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$GMED Insider Trading Activity

$GMED insiders have traded $GMED stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $GMED stock by insiders over the last 6 months:

KELLY HULLER (EVP, GC, Corporate Secretary) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $2,766,700.
DAVID D DAVIDAR sold 25,000 shares for an estimated $2,019,072

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive GMED Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$GMED Hedge Fund Activity

We have seen 286 institutional investors add shares of $GMED stock to their portfolio, and 209 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MADISON AVENUE PARTNERS, LP removed 1,907,275 shares (-72.7%) from their portfolio in Q1 2026, for an estimated $164,330,814
MILLENNIUM MANAGEMENT LLC added 1,409,031 shares (+601.3%) to their portfolio in Q1 2026, for an estimated $121,402,110
BANK OF MONTREAL /CAN/ removed 1,066,079 shares (-31.6%) from their portfolio in Q1 2026, for an estimated $91,853,366
PARSIFAL CAPITAL MANAGEMENT, LP removed 835,600 shares (-68.3%) from their portfolio in Q1 2026, for an estimated $71,995,296
WALLEYE CAPITAL LLC removed 818,829 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $70,550,306
HOLOCENE ADVISORS, LP added 773,834 shares (+inf%) to their portfolio in Q1 2026, for an estimated $66,673,537
AQR CAPITAL MANAGEMENT LLC added 728,692 shares (+617.1%) to their portfolio in Q1 2026, for an estimated $62,784,102

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$GMED Government Contracts

We have seen $1,355,235 of award payments to $GMED over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PRECISION LENGTHENING LEG SYSTEM: $64,186
PRECISE SYSTEM: $61,379
4570529525!ELSA: $42,475
A GLOBUS PRECISE INTRAMEDULLARY NAIL SYSTEM IS REQUIRED FOR A PATIENT (FOR LIMB LENGTHENING SURGERY): $32,065
4570666374!SABLE: $31,415

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$GMED Congressional Stock Trading

Members of Congress have traded $GMED stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $GMED stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 03/03.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$GMED Analyst Ratings

Wall Street analysts have issued reports on $GMED in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 05/08/2026

To track analyst ratings and price targets for $GMED, check out Quiver Quantitative's $GMED forecast page.

$GMED Price Targets

Multiple analysts have issued price targets for $GMED recently. We have seen 8 analysts offer price targets for $GMED in the last 6 months, with a median target of $103.5.

Here are some recent targets:

An analyst from BMO Capital set a target price of $94.0 on 07/09/2026
Tom Stephan from Stifel set a target price of $80.0 on 07/08/2026
Matt O'Brien from Piper Sandler set a target price of $100.0 on 06/15/2026
David Saxon from Needham set a target price of $117.0 on 05/08/2026
Larry Biegelsen from Wells Fargo set a target price of $103.0 on 05/08/2026
Shagun Singh from RBC Capital set a target price of $120.0 on 05/08/2026
Matt Miksic from Barclays set a target price of $123.0 on 02/25/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.